Layer, Chiang, et al. Genome Biology
Santaris Plans Phase II Trial of miRNA-Targeting HCV Drug
The company has also decided to keep the drug in-house until it has collected data from a phase II study of hepatitis C-infected patients, at which point it will pursue partnerships.
New to GenomeWeb? Register here quickly.